CompletedPhase 2

Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

United States59 participantsStarted 2017-03-01

Plain-language summary

The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).

Who can participate

Age range55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 55 and older * Ability to speak English * Availability to attend baseline and follow-up visit approximately 12 weeks after baseline Exclusion Criteria: * Prior history of heart disease (coronary heart disease, heart failure, atrial fibrillation), stroke, severe renal disease * Use of type I and III antiarrhythmics or digoxin * Current use of magnesium supplements * Any prior history of allergy or intolerance to magnesium * Prior history of inflammatory bowel disease or any severe gastrointestinal disorder

What they're measuring

Change in Premature Atrial Contractions (PACs)

Timeframe: Change from Baseline at 10 weeks

Trial details

NCT IDNCT02837328

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-09-15

Results submitted2019-02-01

View on ClinicalTrials.gov More Premature Atrial Contraction trials